Valero, Cristina http://orcid.org/0000-0003-3397-2888
Lee, Mark
Hoen, Douglas
Wang, Jingming
Nadeem, Zaineb
Patel, Neal
Postow, Michael A.
Shoushtari, Alexander N. http://orcid.org/0000-0002-8065-4412
Plitas, George
Balachandran, Vinod P.
Smith, J. Joshua http://orcid.org/0000-0003-2538-5456
Crago, Aimee M.
Long Roche, Kara C. http://orcid.org/0000-0003-0342-2922
Kelly, Daniel W.
Samstein, Robert M. http://orcid.org/0000-0001-6860-2401
Rana, Satshil
Ganly, Ian
Wong, Richard J.
Hakimi, A. Ari http://orcid.org/0000-0002-0930-8824
Berger, Michael F.
Zehir, Ahmet http://orcid.org/0000-0001-5406-4104
Solit, David B. http://orcid.org/0000-0002-6614-802X
Ladanyi, Marc
Riaz, Nadeem http://orcid.org/0000-0001-9873-5862
Chan, Timothy A.
Seshan, Venkatraman E. http://orcid.org/0000-0002-9258-2698
Morris, Luc G. T. http://orcid.org/0000-0002-4417-2280
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 DE027738)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
The Jayme and Peter Flowers Fund, the Sebastian Nativo Fund, the Catherine and Frederick Adler Junior Faculty Chair, and Cycle for Survival.
Fundación Alfonso Martín Escudero
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA205426, R35 CA232097)
Pershing Square Sohn Cancer Research Foundation, the PaineWebber Chair, Stand Up To Cancer, and the STARR Cancer Consortium,
Article History
Received: 24 June 2020
Accepted: 10 November 2020
First Online: 4 January 2021
Competing interests
: D.H. receives funding from AstraZeneca. M.A.P. reports consulting fees from BMS, Merck, Array BioPharma, Novartis, Incyte, NewLink Genetics and Aduro, honoraria from BMS and Merck and research support from Rgenix, Infinity, BMS, Merck, Array BioPharma, Novartis and AstraZeneca. A.N.S. reports advisory board positions with BMS, Immunocore and Castle Biosciences and institutional research support from BMS, Immunocore and Xcovery. V.P.B. is a recipient of an immuno-oncology translational research grant from Bristol Myers Squibb and is an inventor on a patent application related to work on neoantigen modeling. J.J.S. has received travel support from Intuitive Surgical for fellow education and has served as a clinical advisor to Guardant Health. A.M.C. reports an advisory board position with SpringWorks Therapeutics. A.Z. reports honoraria from Illumina. N.R. reports research support from Pfizer and BMS and consulting fees from Repare Therapeutics, Mirati Therapeutics and Illumina. T.A.C. acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, AN2H and Eisai, has served as an advisor for Bristol Myers Squibb, Illumina, Eisai and AN2H, holds equity in AN2H and is a cofounder of Gritstone Oncology and holds equity in the company. L.G.T.M. reports laboratory research funding from Illumina and AstraZeneca. R.M.S., T.A.C. and L.G.T.M. are inventors on a patent held by the Memorial Sloan Kettering Cancer Center related to the use of TMB in cancer immunotherapy. The remaining authors declare no competing interests.